In the published article, there was an error in Table 1 Baseline characteristics of the participants as published.
Table 1
| Age (year) | 67.5 (63–85) |
| Gender | |
| Male | 491 |
| Female | 571 |
| Exercise | |
| <5,000 steps/d | 356 |
| >5,000 steps/d | 706 |
| BMI | |
| <27.5 | 980 |
| >27.5 | 82 |
| Smoker | 259 |
| Alcohol drinking | |
| <100 ml/w | 799 |
| >100 ml/w | 263 |
| Vitamin K2 co-admin (180 μg/d) | 181 |
| Aspirin co-admin (100 mg/d) | 96 |
| Hyperlipidemia | 1,062 |
| Atherosclerosis | 683 |
Baseline characteristics of the participants.
The corrected Table and correct format appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
nattokinase, atherosclerosis, hyperlipidaemia, anti-atherogenic drug, lipid lowering effect, retrospective study, lipid lowering agent, Nattokinase (NK)
Citation
Chen H, Chen J, Zhang F, Li Y, Wang R, Zheng Q, Zhang X, Zeng J, Xu F and Lin Y (2022) Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Front. Cardiovasc. Med. 9:1076420. doi: 10.3389/fcvm.2022.1076420
Received
21 October 2022
Accepted
07 November 2022
Published
05 December 2022
Volume
9 - 2022
Edited and reviewed by
Baohui Xu, Stanford University, United States
Updates
Copyright
© 2022 Chen, Chen, Zhang, Li, Wang, Zheng, Zhang, Zeng, Xu and Lin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yiguang Lin Yiguang.lin@hotmail.comFeng Xu 13840157712@163.com
This article was submitted to Cardiovascular Therapeutics, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.